Achilles Therapeutics (ACHL)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (0.35%)
Updated Apr 24, 2024 03:57 PM ET
After-Market: $0.78 0.00 (-0.48%) 7:40 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Achilles Therapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 132 | 173 | 266 | 178 | 98 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 14 | 23 | 18 | 10 | 5 |
Total Current Assets | 146 | 197 | 285 | 188 | 103 |
Net Property & Equipment | 9 | 12 | 18 | 13 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 4 | 3 | 0 |
Total Assets | 161 | 220 | 317 | 219 | 105 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 5 | 4 | 6 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 4 | 4 | 4 | 0 |
Accrued Expenses | 8 | 8 | 11 | 7 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 17 | 18 | 19 | 17 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 4 | 8 | 12 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 19 | 23 | 28 | 30 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 415 | 409 | 402 | 235 | 118 |
Retained Earnings | -260 | -190 | -119 | -58 | -25 |
Other Equity | -13 | -22 | 7 | 12 | 8 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 142 | 197 | 290 | 189 | 101 |
Total Liabilities & Shareholder's Equity | 161 | 220 | 317 | 219 | 105 |
Total Common Equity | 142 | 197 | 290 | 189 | 101 |
Shares Outstanding | 40.70 | 39.10 | 40.60 | NA | NA |
Book Value Per Share | 3.50 | 5.04 | 7.13 | 0.00 | 0.00 |
Fiscal Year End for Achilles Therapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 132 | 140 | 144 | 158 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 14 | 15 | 32 | 27 |
Total Current Assets | NA | 146 | 155 | 175 | 185 |
Net Property & Equipment | NA | 9 | 10 | 11 | 12 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 3 | 3 | 3 |
Total Assets | NA | 161 | 175 | 198 | 208 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 5 | 7 | 8 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 5 | 5 | 4 |
Accrued Expenses | NA | 8 | 8 | 8 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 17 | 18 | 19 | 18 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 3 | 4 | 4 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 19 | 22 | 24 | 22 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 415 | 414 | 412 | 411 |
Retained Earnings | NA | -260 | -241 | -225 | -208 |
Other Equity | NA | -13 | -19 | -14 | -18 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 142 | 153 | 174 | 185 |
Total Liabilities & Shareholder's Equity | NA | 161 | 175 | 198 | 208 |
Total Common Equity | 0 | 142 | 153 | 174 | 185 |
Shares Outstanding | 39.80 | 40.70 | 40.90 | 40.90 | 40.90 |
Book Value Per Share | 0.00 | 3.50 | 3.75 | 4.25 | 4.53 |